1. X
  2. Memorial Sloan Kettering Cancer Center
Log inSign up
Memorial Sloan Kettering Cancer Center
27.2K posts
Memorial Sloan Kettering Cancer Center profile banner
user avatar

Memorial Sloan Kettering Cancer Center

@MSKCancerCenter
Where you’re treated first, matters. To make an appointment: 877-871-9362
New York, New York
mskcc.org/news
Joined March 2009
1,927
Following
103.9K
Followers
RepliesRepliesMediaMedia

Log in or sign up for X

See what’s happening and join the conversation

Continue with phone
or
Log in with username or email
Terms·Privacy·Cookies·Accessibility·Ads Info·© 2026 X Corp.
  • user avatar
    Memorial Sloan Kettering Cancer Center
    @MSKCancerCenter
    Aug 26
    The @FDA has approved #daraxonrasib for certain patients with metastatic pancreatic cancer. MSK’s @EileenMOReilly led the phase 3 trial at MSK showing it doubled median survival compared with chemotherapy. “To date in my career, I have not seen this level of benefit from any
    Image
  • user avatar
    Memorial Sloan Kettering Cancer Center
    @MSKCancerCenter
    Aug 21
    New clinical trial data led by MSK’s Dr. Robert Motzer supports a novel combination therapy for patients with advanced clear cell renal cell carcinoma whose disease progressed after immunotherapy. The findings, published in @TheLancet, point to a potential new treatment option.
    Image
  • user avatar
    Memorial Sloan Kettering Cancer Center
    @MSKCancerCenter
    Aug 17
    New research from MSK uncovers why some leukemia patients stop responding to new drugs; examines how bone’s hardness shapes the immune battle against metastasis; shows how a telehealth tobacco treatment program helps cancer patients quit smoking; and more: bit.ly/3U61gGA
    Image
  • user avatar
    Memorial Sloan Kettering Cancer Center
    @MSKCancerCenter
    Aug 14
    🚨 Bad News for Cancer: Hear from MSK cancer biologist Dr. Scott Lowe and MSK senior scientist Dr. Aveline Filliol as they share research about an early stage #CART cell technique designed to target a cell surface protein called #uPAR that shrank solid tumors in laboratory
    Image
    00:00
  • user avatar
    Memorial Sloan Kettering Cancer Center
    @MSKCancerCenter
    Aug 10
    The @US_FDA has expanded approval of Pluvicto® (¹⁷⁷Lu-PSMA-617) as an initial treatment for people with metastatic prostate cancer whose tumors are positive for the PSMA protein. The approval is based on results from the phase 3 PSMAddition trial, led in the U.S. by MSK
    Image
Advertisement
Advertisement